PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose

Sui Seng Tee, Jae Mo Park, Ralph E. Hurd, Kyle R. Brimacombe, Matthew B. Boxer, Tarik F. Massoud, Brian K. Rutt, Daniel M. Spielman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cancer metabolism has emerged as an increasingly attractive target for interfering with tumor growth. Small molecule activators of pyruvate kinase isozyme M2 (PKM2) suppress tumor formation but have an unknown effect on established tumors. We demonstrate that TEPP-46, a PKM2 activator, results in increased glucose consumption, providing the rationale for combining PKM2 activators with the toxic glucose analog, 2-deoxy-D-glucose (2-DG). Combination treatment resulted in reduced viability of a range of cell lines in standard cell culture conditions at concentrations of drugs that had no effect when used alone. This effect was replicated in vivo on established subcutaneous tumors. We further demonstrated the ability to detect acute metabolic differences in combination treatment using hyperpolarized magnetic resonance spectroscopy (MRS). Combination treated tumors displayed a higher pyruvate to lactate 13C-label exchange 2 hr post-treatment. This ability to assess the effect of drugs non-invasively may accelerate the implementation and clinical translation of drugs that target cancer metabolism.

Original languageEnglish (US)
Pages (from-to)90959-90968
Number of pages10
JournalOncotarget
Volume8
Issue number53
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pyruvate Kinase
Deoxyglucose
Isoenzymes
Growth
Neoplasms
Pharmaceutical Preparations
Glucose
Poisons
Pyruvic Acid
Lactic Acid
Magnetic Resonance Spectroscopy
Cell Culture Techniques
Cell Line

Keywords

  • Cancer metabolism
  • Hyperpolarized MRI
  • Metabolic imaging
  • Molecular imaging
  • PKM2

ASJC Scopus subject areas

  • Oncology

Cite this

Tee, S. S., Park, J. M., Hurd, R. E., Brimacombe, K. R., Boxer, M. B., Massoud, T. F., ... Spielman, D. M. (2017). PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose. Oncotarget, 8(53), 90959-90968. https://doi.org/10.18632/oncotarget.19630

PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose. / Tee, Sui Seng; Park, Jae Mo; Hurd, Ralph E.; Brimacombe, Kyle R.; Boxer, Matthew B.; Massoud, Tarik F.; Rutt, Brian K.; Spielman, Daniel M.

In: Oncotarget, Vol. 8, No. 53, 01.01.2017, p. 90959-90968.

Research output: Contribution to journalArticle

Tee, SS, Park, JM, Hurd, RE, Brimacombe, KR, Boxer, MB, Massoud, TF, Rutt, BK & Spielman, DM 2017, 'PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose', Oncotarget, vol. 8, no. 53, pp. 90959-90968. https://doi.org/10.18632/oncotarget.19630
Tee SS, Park JM, Hurd RE, Brimacombe KR, Boxer MB, Massoud TF et al. PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose. Oncotarget. 2017 Jan 1;8(53):90959-90968. https://doi.org/10.18632/oncotarget.19630
Tee, Sui Seng ; Park, Jae Mo ; Hurd, Ralph E. ; Brimacombe, Kyle R. ; Boxer, Matthew B. ; Massoud, Tarik F. ; Rutt, Brian K. ; Spielman, Daniel M. / PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose. In: Oncotarget. 2017 ; Vol. 8, No. 53. pp. 90959-90968.
@article{b013a726ddd640e6abf0fa3e8ea83f94,
title = "PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose",
abstract = "Cancer metabolism has emerged as an increasingly attractive target for interfering with tumor growth. Small molecule activators of pyruvate kinase isozyme M2 (PKM2) suppress tumor formation but have an unknown effect on established tumors. We demonstrate that TEPP-46, a PKM2 activator, results in increased glucose consumption, providing the rationale for combining PKM2 activators with the toxic glucose analog, 2-deoxy-D-glucose (2-DG). Combination treatment resulted in reduced viability of a range of cell lines in standard cell culture conditions at concentrations of drugs that had no effect when used alone. This effect was replicated in vivo on established subcutaneous tumors. We further demonstrated the ability to detect acute metabolic differences in combination treatment using hyperpolarized magnetic resonance spectroscopy (MRS). Combination treated tumors displayed a higher pyruvate to lactate 13C-label exchange 2 hr post-treatment. This ability to assess the effect of drugs non-invasively may accelerate the implementation and clinical translation of drugs that target cancer metabolism.",
keywords = "Cancer metabolism, Hyperpolarized MRI, Metabolic imaging, Molecular imaging, PKM2",
author = "Tee, {Sui Seng} and Park, {Jae Mo} and Hurd, {Ralph E.} and Brimacombe, {Kyle R.} and Boxer, {Matthew B.} and Massoud, {Tarik F.} and Rutt, {Brian K.} and Spielman, {Daniel M.}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19630",
language = "English (US)",
volume = "8",
pages = "90959--90968",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "53",

}

TY - JOUR

T1 - PKM2 activation sensitizes cancer cells to growth inhibition by 2-deoxy-D-glucose

AU - Tee, Sui Seng

AU - Park, Jae Mo

AU - Hurd, Ralph E.

AU - Brimacombe, Kyle R.

AU - Boxer, Matthew B.

AU - Massoud, Tarik F.

AU - Rutt, Brian K.

AU - Spielman, Daniel M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Cancer metabolism has emerged as an increasingly attractive target for interfering with tumor growth. Small molecule activators of pyruvate kinase isozyme M2 (PKM2) suppress tumor formation but have an unknown effect on established tumors. We demonstrate that TEPP-46, a PKM2 activator, results in increased glucose consumption, providing the rationale for combining PKM2 activators with the toxic glucose analog, 2-deoxy-D-glucose (2-DG). Combination treatment resulted in reduced viability of a range of cell lines in standard cell culture conditions at concentrations of drugs that had no effect when used alone. This effect was replicated in vivo on established subcutaneous tumors. We further demonstrated the ability to detect acute metabolic differences in combination treatment using hyperpolarized magnetic resonance spectroscopy (MRS). Combination treated tumors displayed a higher pyruvate to lactate 13C-label exchange 2 hr post-treatment. This ability to assess the effect of drugs non-invasively may accelerate the implementation and clinical translation of drugs that target cancer metabolism.

AB - Cancer metabolism has emerged as an increasingly attractive target for interfering with tumor growth. Small molecule activators of pyruvate kinase isozyme M2 (PKM2) suppress tumor formation but have an unknown effect on established tumors. We demonstrate that TEPP-46, a PKM2 activator, results in increased glucose consumption, providing the rationale for combining PKM2 activators with the toxic glucose analog, 2-deoxy-D-glucose (2-DG). Combination treatment resulted in reduced viability of a range of cell lines in standard cell culture conditions at concentrations of drugs that had no effect when used alone. This effect was replicated in vivo on established subcutaneous tumors. We further demonstrated the ability to detect acute metabolic differences in combination treatment using hyperpolarized magnetic resonance spectroscopy (MRS). Combination treated tumors displayed a higher pyruvate to lactate 13C-label exchange 2 hr post-treatment. This ability to assess the effect of drugs non-invasively may accelerate the implementation and clinical translation of drugs that target cancer metabolism.

KW - Cancer metabolism

KW - Hyperpolarized MRI

KW - Metabolic imaging

KW - Molecular imaging

KW - PKM2

UR - http://www.scopus.com/inward/record.url?scp=85032698088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032698088&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19630

DO - 10.18632/oncotarget.19630

M3 - Article

C2 - 29207616

AN - SCOPUS:85032698088

VL - 8

SP - 90959

EP - 90968

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 53

ER -